**Allocate mean age related utility weight for adult population to additional survival in this patient group**

This is based on i) the mean age of diagnosis for renal cell using the ICD codes CD64:66, 68 as in the assessment report and ONS data for cancer registrations 2004 and ii) weights from the York MVH study (Kind, Hardman and Macran (1999) CHE Discussion paper 172)

*mean age (yrs) at*
*diagnosis:*        66 males     67 females
*utility in this age group*        0.78

| *Scenario* | *IC* | *I LYG* | *IQ (original)* | *ICER (origin* | *IQ (max)* | *ICER (max* | *Relative weights* | | | |
| | | | | | | | *Original Q* | | *max Q* | |
| Sunitinib vs IFN, using all final ITT data in Assessment Group model: | | | | | | | | | | |
| | 20868 | 0.22 | 0.2 | 104340 | 0.1716 | 121608 | 5.22 | 3.48 | 6.08 | 4.05 |
| Sunitinib vs IFN, using Committee's preferred assumptions (and no restriction on time of administration of IFN): | | | | | | | | | | |
| | 31921 | 0.86 | 0.59 | 54103 | 0.6708 | 47586 | 2.71 | 1.80 | 2.38 | 1.59 |
| Temsirolimus vs IFN, using manufacturer's model with Assessment Group IFN administration costs | | | | | | | | | | |
| | 13717 | 0.221 | 0.134 | 102366 | 0.17238 | 79574 | 5.12 | 3.41 | 3.98 | 2.65 |
| Sorafenib vs BSC, using 'failed IFN' subgroup with patient access scheme and new price | | | | | | | | | | |
| | 20153 | 0.425643 | 0.31 | 65929 | 0.33200154 | 60702 | 3.25 | 2.17 | 3.04 | 2.02 |